Skip to main content
    • Foundayo

    What Is Foundayo? How Orforglipron Works for Weight Loss

    What is Foundayo? Orforglipron is Eli Lilly's once-daily GLP-1 weight loss tablet. How it works, doses, side effects and who can take it in the UK.

    Jimah Alsaai MPharmJimah Alsaai MPharmSuperintendent Pharmacist
    GPhC 2232652
    Reviewed November 2026
    8 min read

    Start your free consultation with a GPhC-registered pharmacist.

    Begin consultation

    Short answer: Foundayo is the brand name of orforglipron, a once-daily GLP-1 weight loss tablet made by Eli Lilly. It acts on the parts of the brain that regulate appetite, so you feel fuller and tend to eat less.

    The MHRA authorised it on 10 August 2026 for weight management in adults with a BMI of 30 or above, or 27 to under 30 with a weight-related condition, alongside a reduced-calorie diet and more activity, and for type 2 diabetes. You take one tablet a day at any time, with or without food (UK product information, sections 4.1, 4.2 and 5.1).

    This guide explains what Foundayo is, how it works, its doses, how it differs from Wegovy tablets and the weekly injections, its side effects and who should not take it, as of November 2026.

    What is Foundayo?

    Foundayo is a prescription-only weight loss medicine whose active substance is orforglipron. It is a film-coated tablet, and it comes in six strengths, from 0.8mg to 17.2mg.

    A Foundayo 0.8mg pack
    The 0.8mg pack, the starting dose.

    The UK product information describes orforglipron as an oral non-peptide GLP-1 receptor agonist. In plain words, it is a different kind of molecule from the GLP-1 hormone, but it switches on the same receptor.

    Foundayo is an Eli Lilly medicine: an Eli Lilly company holds its UK licence, as it does for Mounjaro. This medicine carries the black triangle (▼) for additional monitoring. Report any suspected side effects via the MHRA Yellow Card scheme.

    How does Foundayo work?

    Foundayo works mainly on appetite. The MHRA explains that it mimics GLP-1, a hormone the body releases after eating, and acts on the areas of the brain that regulate appetite, helping people feel fuller for longer, with less hunger and fewer food cravings.

    1. Orforglipron acts like GLP-1A hormone your body releases after you eat
    2. It switches on GLP-1 receptors in the brainIn the areas that regulate appetite
    3. You feel fuller and less hungrySo you tend to eat less, alongside a reduced-calorie diet and more activity
    How Foundayo works for weight loss, in plain words. Sources: Foundayo SmPC, section 5.1, and the MHRA's announcement of 10 August 2026.

    It also slows how quickly your stomach empties. The UK product information says this effect is largest after the first dose and lessens over time. In type 2 diabetes, it helps the body release insulin when blood sugar is high.

    Its half-life, the time for the level in your blood to halve, is about 29 to 49 hours, which suits a tablet once a day. The level settles after about a week of daily doses (SmPC section 5.2).

    The product information found no clinically relevant effect of food on how much reaches your blood, and it sets no food or water restrictions. For how GLP-1 medicines work in general, see our guide to what a GLP-1 medication is.

    What is Foundayo used for in the UK?

    Foundayo is licensed for weight management, including weight loss and keeping weight off, and for type 2 diabetes. For weight, the licence covers adults with a BMI of 30 or above, or 27 to under 30 with at least one weight-related condition.

    The conditions it names include prediabetes, type 2 diabetes, high blood pressure, abnormal blood fats, obstructive sleep apnoea and heart or circulation disease. Treatment always goes alongside a reduced-calorie diet and more physical activity.

    For type 2 diabetes, it is licensed to improve blood sugar control in adults whose diabetes is not well controlled, on its own or with other diabetes medicines. We supply it through our weight-loss consultation to adults aged 18 to 84. Not sure of your BMI? Use our BMI calculator.

    The approval itself, and what it means for availability, is in our guide to Foundayo's UK approval.

    How do you take Foundayo?

    Foundayo is one tablet a day, at a time that suits you. This is the counselling we give with it:

    One tablet once daily, at any time of day, with or without food. Swallow it whole with water. Never split, crush or chew it.

    Missed a dose? Take it as soon as you remember on the same day. If you only remember the next day, skip it. Never take two tablets in one day.

    Storage: keep the tablets in the original pack. No fridge needed.

    You will stay on each dose step for a minimum of 30 days, and we review you before every dose increase.

    Timing, interactions and what to do if you stop are set out step by step in how to take Foundayo.

    What doses does Foundayo come in?

    Foundayo starts at 0.8mg once a day and goes up in steps of at least 30 days, to a highest dose of 17.2mg. Not everyone goes up to the top dose: above 5.5mg, each step depends on how well it works for you and how well you tolerate it.

    Foundayo tabletWhen it is usedTrial capsule it matches
    0.8mgThe starting dose, for at least 30 days1mg
    2.5mgAfter at least 30 days on 0.8mg3mg
    5.5mgAfter at least 30 days on 2.5mg6mg
    9mgIf needed, after at least 30 days on 5.5mg, depending on how well it works and how well you tolerate it12mg
    14.5mgIf needed, after at least 30 days on 9mg, depending on how well it works and how well you tolerate it24mg
    17.2mgIf needed, after at least 30 days on 14.5mg, depending on how well it works and how well you tolerate it. The highest dose36mg

    The trials gave capsules, which are not interchangeable with the tablets milligram for milligram, so the product information pairs each tablet with the capsule that has the same effect (SmPC section 5.1, Table 2).

    You never take more than one tablet a day. Some medicines cap the dose at 9mg, such as clarithromycin, itraconazole, ketoconazole and ciclosporin, and ritonavir and telaprevir should be avoided with it.

    Others, such as St John's wort, rifampicin, phenytoin and carbamazepine, can make Foundayo work less well, and the product information says to avoid them with it (SmPC sections 4.2 and 4.5). Our guide to medicines that interact with weight loss treatment covers the rest.

    Wondering whether Foundayo could suit you? Our consultation asks about your health, your weight and the medicines you take, and a GPhC-registered pharmacist reviews every answer before anything is supplied. If they cannot approve your order, we refund you in full.

    Check your eligibility

    How much weight do people lose on Foundayo?

    In the ATTAIN-1 trial (New England Journal of Medicine, 2025), 3,127 adults without type 2 diabetes took orforglipron or placebo for 72 weeks, with diet and activity advice for everyone.

    In ATTAIN-1 (2025), on the dose matching Foundayo 17.2mg, the average weight loss was 12.4% if everyone had kept taking it, against 0.9% on placebo, as the UK product information gives it. Counting everyone who started, including people who stopped, it was 11.2% against 2.1%. Individual results vary.

    Trials report two averages. One estimates the result if everyone had kept taking their medicine (the main figure in the Mounjaro and Foundayo product information; Wegovy's gives it in a note under its tables). The other counts everyone who started, including people who stopped: on the medicine it is lower, and on placebo it can be higher.

    How Foundayo sits beside other medicines' separate trials is set out in our Foundayo vs Wegovy pill and Foundayo vs Mounjaro guides.

    How is Foundayo different from Wegovy tablets and the weekly injections?

    The practical difference most people notice is how each is taken. Foundayo has no food or water rules, the Wegovy tablet needs an empty stomach and a wait, and Mounjaro and Wegovy injections are once a week.

    QuestionFoundayoWegovy tabletsMounjaro and Wegovy injections
    Active substanceOrforglipronSemaglutideTirzepatide (Mounjaro) or semaglutide (Wegovy)
    What it acts onThe GLP-1 receptorThe GLP-1 receptorGIP and GLP-1 receptors (Mounjaro), the GLP-1 receptor (Wegovy)
    How oftenOne tablet a dayOne tablet a dayOne injection a week
    Food and waterAny time of day, with or without foodOn an empty stomach after at least 8 hours without food, with up to 120ml of water, then 30 minutes before eating, drinking or other medicinesAny time of day, with or without meals
    Starting dose0.8mg a day1.5mg a day2.5mg a week (Mounjaro), 0.25mg a week (Wegovy)

    Each of these medicines was studied in its own trials, so this guide does not rank them. Which suits you depends on your health, your other medicines and how you would rather take it, and a GPhC-registered pharmacist decides whether it is suitable for you.

    More on each: Wegovy tablets, Wegovy injections and our guide to the licensed weight loss medicines in the UK.

    What are the side effects of Foundayo?

    The most common side effects affect the stomach and gut, and the UK product information says they are mostly mild or moderate. Nausea, vomiting, diarrhoea and constipation are very common in the first few weeks and after each dose increase. Eat smaller meals, avoid very fatty food, and keep well hydrated.

    • Very common (more than 1 in 10 people): feeling sick, constipation, diarrhoea, being sick, indigestion and stomach pain.
    • Common (up to 1 in 10): dizziness, headache, a fast pulse, low blood pressure, bloating, burping, reflux or heartburn, wind, gallstones, hair loss, tiredness and raised pancreatic enzymes in blood tests.
    • Uncommon (up to 1 in 100): inflammation of the pancreas (acute pancreatitis), a change in taste, and an unpleasant or abnormal feeling when the skin is touched.

    Low blood sugar can happen if you also take insulin or a sulfonylurea for diabetes, and your doctor may lower their dose. How long side effects last and what helps are in our Foundayo side effects guide.

    Who should not take Foundayo?

    You must not take Foundayo if you are allergic to orforglipron or any of its other ingredients: that is the contraindication in the UK product information. It should not be used in pregnancy or while breastfeeding, and it is stopped at least 3 weeks before a planned pregnancy.

    If you could become pregnant, use effective contraception while you take it (SmPC section 4.6).

    If you use the oral contraceptive pill, use a non-oral method or add a barrier method such as condoms for 30 days after starting treatment and for 30 days after each dose increase.

    The product information does not recommend it with severe liver disease or with heart failure that leaves you breathless at rest, and it asks for caution after pancreatitis and with severe stomach or bowel disease, such as severe gastroparesis. Its safety and effectiveness in under 18s have not been established.

    Through our service, we do not supply Foundayo, or any of our weight loss medicines, to anyone with:

    • Cirrhosis or severe liver disease (liver failure, or told you are Child-Pugh C)
    • Chronic kidney disease (eGFR < 30 mL/min)
    • Heart failure that leaves you breathless at rest or unable to do any activity (NYHA class 4)
    • History of pancreatitis
    • Medullary thyroid cancer (MTC) or MEN-2, in you or a blood relative
    • Currently having chemotherapy, immunotherapy or other active cancer treatment
    • Type 1 diabetes
    • An eating disorder diagnosed by a doctor, now or in the past (anorexia, bulimia, binge eating disorder)
    • Gallbladder problems right now: gallstones causing pain, cholecystitis, or waiting for gallbladder surgery
    • Gastroparesis (delayed stomach emptying) or a previous bowel obstruction

    Is Foundayo available on the NHS?

    Not for weight management, as of November 2026. The MHRA said when it approved Foundayo that it was not then available on the NHS, and that decisions on NHS use would follow an evaluation by NICE.

    NICE is appraising orforglipron for overweight and obesity (ID6516) and expects to publish its guidance on 27 January 2027. Who can get weight loss medicines on the NHS now is in our guide to weight loss injections on the NHS.

    How can you get Foundayo from Solira?

    Foundayo is prescription-only, so it is supplied after a consultation, not bought over the counter. You complete our online weight-loss consultation, and a GPhC-registered pharmacist reviews your answers before anything is supplied.

    Where it is suitable, QuickCare Pharmacy, the registered pharmacy that dispenses Solira orders (GPhC 9013213), sends it to you. Our price for every strength is in our Foundayo price guide, and how supply works step by step is in how to get Foundayo in the UK.

    Already taking Foundayo or another weight loss medicine?

    If you already take Foundayo elsewhere, you usually carry on with it rather than starting again at 0.8mg, once your pharmacist has checked proof of your last treatment. Our guide to restarting after a break explains the dose after time off.

    Foundayo's UK product information gives one starting dose, 0.8mg, and no dose for moving from another medicine, so if you take a different weight loss medicine now, a GPhC-registered pharmacist decides how you would start. See also our weight loss treatments.

    When should you speak to your pharmacist or doctor?

    Seek urgent medical help if you have severe, persistent abdominal pain that may spread to your back (possible pancreatitis), sudden loss of vision or loss of part of your field of vision (NAION), pain in the upper right of your tummy with fever or yellowing of the skin or eyes (gallbladder), or signs of dehydration such as dizziness, dry mouth or passing much less urine.

    Stop your treatment and seek urgent medical help if you experience: severe, persistent stomach pain, especially spreading to your back, with or without vomiting. This can be a sign of pancreatitis. Sudden pain in the upper right of your tummy, fever, or yellowing of the skin or eyes: possible gallbladder problems. Sudden loss of vision, or loss of part of your field of vision: seek same-day eye assessment. Swelling of the face or lips, difficulty breathing, or a widespread rash: call 999.

    Seek advice promptly if you notice: signs of dehydration during vomiting or diarrhoea (dizziness, reduced urination, dry mouth): keep sipping fluids, as dehydration can affect your kidneys; palpitations or a racing heartbeat at rest; a new neck lump, swelling, or hoarseness. If you have type 2 diabetes and use insulin or a sulfonylurea, know the signs of low blood sugar (sweating, shaking, sudden hunger, confusion) and treat promptly.

    Before any operation: tell your surgical or anaesthetic team you take a GLP-1 medicine. It slows stomach emptying, which matters for anaesthesia.

    Tell your pharmacist about every medicine you take, including ones you buy yourself, before you start Foundayo and before you start anything new while you take it.

    Urgent help, genuine medicines and the official leaflets

    Frequently asked questions

    Foundayo is the brand name of orforglipron, a once-daily GLP-1 weight loss tablet made by Eli Lilly. The MHRA authorised it on 10 August 2026 for weight management in adults with a BMI of 30 or above, or 27 to under 30 with a weight-related condition, alongside a reduced-calorie diet and more physical activity, and for adults with type 2 diabetes that is not well controlled. It is a prescription-only medicine.

    Yes. Orforglipron is the active substance, and Foundayo is the brand name it is sold under in the UK. The UK product information describes orforglipron as an oral non-peptide GLP-1 receptor agonist: it switches on the same receptor as the GLP-1 hormone your body releases after eating.

    Foundayo acts like GLP-1, a hormone your body releases after you eat. It switches on GLP-1 receptors in the parts of the brain that regulate appetite, which the MHRA says helps people feel fuller for longer, with less hunger and fewer food cravings, so they tend to eat less. It also slows stomach emptying, most after the first dose, and in type 2 diabetes it lowers blood sugar when it is high.

    Yes. The MHRA authorised Foundayo (orforglipron) on 10 August 2026, for weight management and for type 2 diabetes. It is available privately on prescription, after a consultation reviewed by a GPhC-registered pharmacist, and it is not currently available on the NHS for weight management.

    A tablet. Foundayo is one film-coated tablet a day, taken at any time of day, with or without food, swallowed whole. It comes in six strengths, from 0.8mg to 17.2mg, and you stay on each dose for at least 30 days before any increase.

    Yes. Foundayo is an Eli Lilly medicine. The UK product information names Eli Lilly Nederland B.V. as the marketing authorisation holder, as it does for Mounjaro, and the MHRA granted the licence to Eli Lilly on 10 August 2026.

    Neither is better for everyone. They are different medicines, tested in separate trials in different people, so their results are not a direct comparison. Foundayo is a daily tablet with no food or water rules; Wegovy comes as a weekly injection or a daily tablet taken on an empty stomach with a 30-minute wait before food or drink. Which suits you depends on your health, your other medicines and how you would rather take it, and a GPhC-registered pharmacist decides whether a medicine is suitable for you.

    At Solira a 30-day pack of Foundayo costs £79.99 at the 0.8mg starting dose, rising with each strength to £139.99 at 17.2mg. The price for each dose is the same on your first order and every one after. No introductory prices. Supplied only if your pharmacist decides it is suitable for you. Foundayo is not currently available on the NHS for weight management.

    In the ATTAIN-1 trial (New England Journal of Medicine, 2025), 3,127 adults without type 2 diabetes took orforglipron or placebo for 72 weeks, with diet and activity advice for everyone. On the dose matching Foundayo 17.2mg, the average weight loss was 12.4% if everyone had kept taking it, against 0.9% on placebo, as the UK product information gives it. Counting everyone who started, including people who stopped, it was 11.2% against 2.1%. Individual results vary.

    Keep reading

    Ready to start?

    Start your free consultation with a GPhC-registered pharmacist.

    Begin consultation

    Follow us on Instagram (opens Instagram in a new tab)